NCT00243191View on ClinicalTrials.gov

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Dermatofibrosarcoma Protuberans
Interventions
DRUG

imatinib mesylate

400 mg orally twice a day for 10 - 14 days

Trial Locations (4)

19106

Pennsylvania Onc/Hem Assoc., Philadelphia

33612

H. Lee Moffitt Cancer Center, Tampa

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

Sarcoma Alliance for Research through Collaboration

OTHER

NCT00243191 - Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans | Biotech Hunter | Biotech Hunter